Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Ezetimibe

Brand: 
NICE TA: 385
Indication: Primary heterozygous-familial and non-familial hypercholesterolaemia (NICE TA385)
Disease category: Cardiovascular system
Commissioning responsibility: No
PbR excluded: CCG

Background

Ezetimibe monotherapy is recommended as an option for treating primary (heterozygous‑familial or non‑familial) hypercholesterolaemia in adults in whom statin therapy is contraindicated or not tolerated. Ezetimibe, co-administered with initial statin therapy, is recommended as an option for treating primary (heterozygous‑familial or non‑familial) hypercholesterolaemia in adults who have started statin therapy when:
•serum total or low‑density lipoprotein cholesterol, is not appropriately controlled after dose titration of initial statin therapy or because dose titration is limited by intolerance OR
•a change from initial statin therapy to an alternative statin is being considered.

Recommendation

LMMG recommendation: Green
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care

Supporting documents:

NICE TA385 - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Green

Green

Green

Green

Green

Green